SK3 Group Tests New Cannabinoid-based Skin Care Products


Ryan Allway

January 14th, 2014

News, Top News


SK3 Group, Inc. (OTC Pink: SKTO) announced that it’s seeking participants to test their new proprietary cannabinoid-based skin care products. Numerous scientific studies, as well as a host of anecdotal evidence, have shown that phyto-cannabinoids, and other elements of cannabis / hemp, are active against various types of skin disease.

Read the full press release here:

SK3 Group, Inc.’s (OTC Pink: SKTO) subsidiary Medical Greens (“the Company”) is pleased to announce that Berkeley Bio-Organic Research Laboratories is seeking participants to test their new proprietary cannabinoid-based skin care products — Dharmanol™ Topikoil™, and T-Hydrocan™ Topikoil™.

Numerous scientific studies, as well as a host of anecdotal evidence, have shown that phyto-cannabinoids, and other elements of cannabis / hemp, are active against various types of skin disease. Research by Manuel Guzman at Complutense University in Madrid, Spain has shown that cannabinoids decreased cancer cell proliferation and spreading, decreased density of blood vessels that provide nutrients to tumors, increased cancer cell death, and inhibited tumor-cell metastatic spreading into nearby organs. Much anecdotal evidence on the internet and elsewhere has shown that cannabis oil, when placed on a wart, mole, discoloration, or other growth, can cause numerous types of skin imperfections to simply disappear in just a few weeks with daily treatment.

Berkeley Bio will be testing two types of its proprietary Topikoil™. T-Hydrocan™ Topikoil™ will be made with a substantial dose of whole-plant cannabis extract containing fully activated (decarboxylated) cannabinoids, as well as a wide array of terpenes, terpenoids, and other steam-soluble elements of cannabis / hemp. Dharmanol™ Topikoil™ contains non-psychoactive CBD (cannabidiol) and a wide array of other non-psychoactive cannabinoids from cannabis / hemp.

While the initial testing and rollout will focus on medical cannabis patients in California, the Company intends to roll out Dharmanol™ Topikoil™ nationwide based on the applicable regulations of each state and the US Government.

Those wishing to participate will be provided with several different topical preparations (lotions / salves) and will be required to live in California and keep accurate records, including taking before and after pictures. The testing will begin in one to two months. To sign up, please email your contact information to [email protected].

“We are very pleased to be announcing these new products,” said Artemus Mayor, President of the Company. “Research has shown very significant effectiveness of medical cannabis against a wide variety of skin ailments, and the stories on the Internet of people casually treating skin imperfections with cannabis topicals abound. Not only is this product chemically different than other similar products on the market, but our new products will have consistent, measurable medical cannabis content that should lead to more effective and targeted dosing. Adding this new delivery system to our Dharmanol™ line of products will substantially increase our market reach into new areas, directly benefiting our bottom line. In addition, our experience with these new products will assist in our development of an extended release transdermal patch product as well as other products.”

FDA Statement
The statements in this document have not been evaluated or approved by the FDA. The products and statements referenced in this document are not intended to diagnose, treat, cure, or prevent any disease.

About SK3
SK3 is a healthcare logistics and fulfillment consultancy focused on the delivery of alternative care and medicine. With seasoned management, breakthrough technology and best practices, SK3 brings standardization and transparency to this rapidly growing segment of the alternative care field.

Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company’s current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company’s business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading